J Slof1, R Díez Valle2, J Galván3. 1. Universidad Autónoma de Barcelona, Bellaterra, Cerdanyola del Vallès, España. Electronic address: ericjohn.slof@uab.cat. 2. Departamento de Neurocirugía, Clínica Universidad de Navarra, Pamplona, España. 3. Laboratorios Gebro Pharma S.A., Barcelona, España.
Abstract
OBJECTIVE: This study evaluates the cost-effectiveness of 5-aminolevulinic acid (5-ALA, Gliolan®) in patients undergoing surgery for malignant glioma, in standard clinical practice conditions in Spain. MATERIAL AND METHODS: Cost-effectiveness ratios were determined in terms of incremental cost per complete resection (CR) and incremental cost per additional quality-adjusted life year (QALY), based on data collected in the VISIONA observational study. RESULTS: Incremental cost with 5-ALA versus conventional surgery using white light only amounts to € 4550 per additional CR achieved and € 9021 per QALY gained. A sensitivity analysis shows these results to be robust. CONCLUSION: Malignant glioma surgery guided by 5-ALA fluorescence entails a moderate increase in hospital costs compared to current surgical practice and can be considered a cost-effective innovation.
OBJECTIVE: This study evaluates the cost-effectiveness of 5-aminolevulinic acid (5-ALA, Gliolan®) in patients undergoing surgery for malignant glioma, in standard clinical practice conditions in Spain. MATERIAL AND METHODS: Cost-effectiveness ratios were determined in terms of incremental cost per complete resection (CR) and incremental cost per additional quality-adjusted life year (QALY), based on data collected in the VISIONA observational study. RESULTS: Incremental cost with 5-ALA versus conventional surgery using white light only amounts to € 4550 per additional CR achieved and € 9021 per QALY gained. A sensitivity analysis shows these results to be robust. CONCLUSION:Malignant glioma surgery guided by 5-ALA fluorescence entails a moderate increase in hospital costs compared to current surgical practice and can be considered a cost-effective innovation.
Authors: Daniel M Fountain; Andrew Bryant; Damiano Giuseppe Barone; Mueez Waqar; Michael G Hart; Helen Bulbeck; Ashleigh Kernohan; Colin Watts; Michael D Jenkinson Journal: Cochrane Database Syst Rev Date: 2021-01-04
Authors: Michael D Jenkinson; Damiano Giuseppe Barone; Andrew Bryant; Luke Vale; Helen Bulbeck; Theresa A Lawrie; Michael G Hart; Colin Watts Journal: Cochrane Database Syst Rev Date: 2018-01-22
Authors: Quan Zhou; Nynke S van den Berg; Eben L Rosenthal; Michael Iv; Michael Zhang; Johana C M Vega Leonel; Shannon Walters; Naoki Nishio; Monica Granucci; Roan Raymundo; Grace Yi; Hannes Vogel; Romain Cayrol; Yu-Jin Lee; Guolan Lu; Marisa Hom; Wenying Kang; Melanie Hayden Gephart; Larry Recht; Seema Nagpal; Reena Thomas; Chirag Patel; Gerald A Grant; Gordon Li Journal: Theranostics Date: 2021-05-21 Impact factor: 11.556